Tango Therapeutics Jumps 48% After 11 of 12 Pancreatic Cancer Patients See Tumors Shrink
Updated
Updated · Bloomberg · Jun 8
Tango Therapeutics Jumps 48% After 11 of 12 Pancreatic Cancer Patients See Tumors Shrink
2 articles · Updated · Bloomberg · Jun 8
Summary
Tango Therapeutics rose as much as 48% on Monday after saying tumors shrank significantly in 11 of 12 patients with advanced pancreatic cancer treated with its two-drug regimen.
The early study paired Tango’s drug with a Revolution Medicines therapy, and the company said two of the reported responses still await confirmation from a second scan.
Earlier Phase 1/2 data on the same combination in metastatic pancreatic ductal adenocarcinoma had shown 90% progression-free survival at six months, adding context to the latest investor reaction.
With a competitor close behind, can Tango Therapeutics win the high-stakes race to market its new pancreatic cancer drug?
Is this a true pancreatic cancer breakthrough, or another false dawn in a field known for late-stage failures?
Landmark 92% Response Rate in Pancreatic Cancer: New Combination Therapy Targets MTAP Deletion and RAS Mutations
Overview
Tango Therapeutics has reported highly encouraging early clinical trial results for its combination therapy of vopimetostat and daraxonrasib in patients with advanced, MTAP-deleted, RAS-mutant pancreatic cancer. The therapy achieved a remarkable 92% objective response rate, with 90% of patients remaining progression-free at six months. Importantly, the treatment was generally well tolerated, showing a favorable safety profile. These strong efficacy and safety results support earlier preclinical findings that suggested a synergistic effect between PRMT5 and RAS inhibition, marking a potential breakthrough for a disease that has been very difficult to treat.